- Home
- MYNZ vs KPRX Comparison
MYNZ vs KPRX Comparison
Compare MYNZ & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- KPRX
- Stock Information
- Founded
- MYNZ 2021
- KPRX 1998
- Country
- MYNZ Germany
- KPRX United States
- Employees
- MYNZ N/A
- KPRX N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MYNZ Health Care
- KPRX Health Care
- Exchange
- MYNZ Nasdaq
- KPRX Nasdaq
- Market Cap
- MYNZ 7.6M
- KPRX 8.6M
- IPO Year
- MYNZ 2021
- KPRX N/A
- Fundamental
- Price
- MYNZ $2.04
- KPRX $2.99
- Analyst Decision
- MYNZ Buy
- KPRX Strong Buy
- Analyst Count
- MYNZ 2
- KPRX 1
- Target Price
- MYNZ $14.00
- KPRX $10.00
- AVG Volume (30 Days)
- MYNZ 185.7K
- KPRX 62.4K
- Earning Date
- MYNZ 08-05-2025
- KPRX 08-08-2025
- Dividend Yield
- MYNZ N/A
- KPRX N/A
- EPS Growth
- MYNZ N/A
- KPRX N/A
- EPS
- MYNZ N/A
- KPRX N/A
- Revenue
- MYNZ $893,991.00
- KPRX $20,000.00
- Revenue This Year
- MYNZ $26.06
- KPRX N/A
- Revenue Next Year
- MYNZ $4.97
- KPRX N/A
- P/E Ratio
- MYNZ N/A
- KPRX N/A
- Revenue Growth
- MYNZ N/A
- KPRX N/A
- 52 Week Low
- MYNZ $1.34
- KPRX $2.51
- 52 Week High
- MYNZ $19.00
- KPRX $4.80
- Technical
- Relative Strength Index (RSI)
- MYNZ 57.11
- KPRX 47.28
- Support Level
- MYNZ $1.89
- KPRX $2.96
- Resistance Level
- MYNZ $2.25
- KPRX $3.29
- Average True Range (ATR)
- MYNZ 0.22
- KPRX 0.15
- MACD
- MYNZ 0.05
- KPRX 0.01
- Stochastic Oscillator
- MYNZ 76.14
- KPRX 38.78
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.